Rexulti Under Consideration as Maintenance Schizophrenia Treatment

Article

The FDA has accepted for review Otsuka and Lundbeck's supplemental new drug application for a label update to brexipiprazole.

The FDA has accepted for review Otsuka and Lundbeck’s supplemental new drug application for a label update to brexipiprazole (Rexulti).

Rexulti, which is currently indicated as a schizophrenia treatment and as adjunctive therapy to antidepressants for adults with major depressive disorder, could potentially be approved as maintenance treatment for schizophrenia.

The FDA is expected to take action on the labeling update application by September 23, 2016.

The application was accepted by the FDA based on data from a 52-week trial, involving patients who were stabilized on Rexulti and then randomized to receive either continued therapy with Rexulti or placebo.

In the trial, patients who took Rexulti demonstrated a significantly longer time to relapse than the placebo-treated patients.

The most common adverse effects associated with Rexulti include weight gain and akathisia.

Related Videos
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
selling mental health medication to man at pharmacy | Image Credit: Syda Productions - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Image credit: rawpixel.com | stock.adobe.com
Medical team -- Image credit: Flamingo Images | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.